Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Type
Public
HQ
Bagsvaerd, DK
Founded
1923
Size (employees)
42,076 (est)+2%
Novo Nordisk was founded in 1923 and is headquartered in Bagsvaerd, DK
Report incorrect company information

Key People/Management at Novo Nordisk

Lars Rebien Sørensen

Lars Rebien Sørensen

President & Chief Executive Officer
Jesper Brandgaard

Jesper Brandgaard

EVP and Chief Financial Officer
Maziar Mike Doustdar

Maziar Mike Doustdar

EVP of International Operations
Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen

EVP Corporate Developemnt

Novo Nordisk Office Locations

Novo Nordisk has offices in Pensacola, Knoxville, Detroit, Grand Rapids and in 137 other locations
Bagsvaerd, DK (HQ)
Novo Nordisk A/S Novo Allé
Mississauga, CA
300-2680 Skymark Avenue, Floor 3
Beijing, CN
18F, East Tower, World Financial Center, No. 1 East 3rd Ring Middle Road, Chaoyang District
Mainz, DE
Brucknerstrasse 1
Bangalore, IN
Plot No.32, 47-50, EPIP Area, Whitefield
Tokyo, JP
Meiji Yasuda Seimei Bldg. 2-1-1, Marunouchi, Chiyoda-ku
Show all (141)
Report incorrect company information

Novo Nordisk Financials and Metrics

Novo Nordisk Financials

Market capitalization (31-Oct-2017)

123.5 b

Closing share price (31-Oct-2017)

49.9
Novo Nordisk's current market capitalization is $123.5 b.
Show all financial metrics

Novo Nordisk Operating Metrics

FY, 2015FY, 2016

Patients Reached

26.80 m

Phase III Trials Products

6 3

Projects in R&D Pipeline

19 17
Show all operating metrics
Report incorrect company information

Novo Nordisk News and Updates

Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence

In a new approach to the pricing and payer issues beleaguering pharma in general and diabetes drugmakers in particular, Novo Nordisk has teamed up on a project that puts patients with diabetes to work earning discounted copays and other incentives for good behavior.

Novo Nordisk buys blood drug licence to boost anaemic biopharma business

COPENHAGEN, April 5 (Reuters) - Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) programme in a bid to offset declining sales in its biopharmaceutical business.

Novo Nordisk's Tresiba snags label boost that could sharpen its safety edge

Competition in the basal insulin market has been fierce, with new competition and payer pressure stymieing growth in the field. But Novo Nordisk just won an FDA approval that could help it stand out in the crowded category.

Novo Nordisk backs up M&A pledge by appointing deal-minded board chair

Just weeks after Novo Nordisk lost out to Sanofi in a race to buy the pipeline-boosting biotech Ablynx, the Danish drugmaker is far from out of the M&A game. For its new board chairman, Novo chose Helge Lund, an oil-industry veteran with plenty of deals under his belt.

Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study

Novo Nordisk’s closely watched semaglutide has already shown it can spur weight loss in diabetic patients. Now it’s added evidence that it can help nondiabetic obesity patients shed pounds, too.
Show more
Report incorrect company information